It is our distinct pleasure to inform the GHI community that we have been awarded a Phase II SBIR Grant from the National Institutes of Health. As we are also preparing to celebrate our 20th Anniversary, these two events invoke a lot of excitement within our company and what lies ahead, for not GHI only, but the genetics field entirely. We look forward to continuing our development with the help of this grant and assisting researchers and clinicians in their quest for personalized medicine.

Golden Helix, Inc., an industry-leading genomic analytics company that specializes in clinical Next-Gen Sequencing analysis software, has announced today that the National Institutes of Health awarded them a Phase 2 SBIR Grant 2R44 GM125432-02 “Integrating CNV analysis into a NextGen sequencing clinical analytics platform”.

This grant was awarded to develop and refine algorithms and applications to detect copy number variants (CNVs) and other structural variations in Next-Gen Sequencing. Also, it allows us tospearhead further development in combining these types of mutations with clinical interpretation workflows. “The NIH has been a terrific partner and supporter of our company,” states Dr. Andreas Scherer President, and CEO of Golden Helix, Inc. “With the help of the approved funds, we will be able to take calculated risks pushing the currently existing boundaries of the clinical interpretation of Next-Gen Sequencing to the next level. The commitment of this grant gives us the ability to focus the next two years on advancements in this area. As the Principal Investigator of this grant, I want to express my utmost gratitude for this funding.”